Predictive Oncology (POAI) Stock Analysis

What Predictive Oncology does

Predictive Oncology Inc. (POAI), an organization driven by expertise and data, is dedicated to pioneering individualized cancer treatments through the application of artificial intelligence, primarily within the United States. The company conducts its operations across four distinct divisions: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics division offers extensive clinical diagnostic services, including tumor drug response assessments and genomic profiling, alongside contract research focused on patient-centered drug discovery. This latter service leverages active learning technology for foundational discovery, clinical and translational research, clinical trials, and the development and validation of diagnostics. Meanwhile, the zPREDICTA division excels in crafting organ-specific disease models, providing three-dimensional reconstructions of human tissues that accurately mirror various disease states and simulate drug responses, particularly for evaluating anticancer agents. The Soluble segment delivers services centered on High-Throughput Self-Interaction Chromatography, an automated system proficient at screening additives and excipients in protein formulations to ensure the creation of soluble and physically stable biologic therapeutics. This segment also provides protein stability analysis, specialized kits for swift identification of soluble formulations, and proprietary technologies for the detection and elimination of bacterial endotoxins. The Skyline division markets the STREAMWAY System, a fully automated, wall-mounted device designed to substantially minimize healthcare staff's exposure to blood and other infectious fluids in clinical environments. Furthermore, this division conducts research and development and supplies specialized media that supports the ex-vivo growth of cancer cells while maintaining their original DNA/RNA and proteomic signatures. Founded in 2002, the company was formerly known as Precision Therapeutics Inc. until it adopted the name Predictive Oncology Inc. in June 2019. Its corporate headquarters are situated in Eagan, Minnesota.

Key metrics

ETFs linked to POAI

Broad-market and Healthcare sector ETFs an investor holding Predictive Oncology is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how POAI fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Predictive Oncology?

Predictive Oncology trades under the ticker POAI on NASDAQ.

Which exchange is POAI listed on?

POAI is listed on NASDAQ.

What sector does Predictive Oncology operate in?

Predictive Oncology is classified in the Healthcare sector (Medical - Instruments & Supplies industry).

How can PortView help analyze POAI in a portfolio?

PortView shows POAI's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.